Estonian national focal point
The national focal point is located within the Centre for Drugs and Addictions of the National Institute for Health Development. The centre collects, harmonises and analyses data on drugs in Estonia, and disseminates information and cooperates with EU and non-EU national focal points, and other international bodies and organisations.
The Estonian national focal point was EMCDDA certified in September 2023.
News
Events
Publications
Publications related to this partner
The elimination barometer for hepatitis B and C among people who inject drugs is designed to support countries affiliated to the EMCDDA in monitoring their progress towards the Sustainable Development Goal 3.3 and the elimination of viral hepatitis as a major public health threat by 2030.
Heroin remains Europe’s most commonly used illicit opioid and is also the drug responsible for a large share of the health burden attributed to illicit drug consumption.
MDMA is a synthetic drug chemically related to the amphetamines, but with somewhat different effects. In Europe, MDMA use has generally been associated with episodic patterns of consumption in the context of nightlife and entertainment settings.
Amphetamine, methamphetamine and, more recently, synthetic cathinones are all synthetic central nervous system stimulants available on the drug market in Europe.
The market for new psychoactive substances is characterised by the large number of substances that have appeared in this area and that new compounds continue to be detected each year.
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe.
Document library
Media library
Related photos, infographics and videos from our Media library
Contact information
National Institute for Health Development
Ms Katri Abel-Ollo
Tallinn
Estonia